Clinical trials: Gefitinib, completed
Metastatic Cancer
N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy
The metastatic lesions may be very different from the primary tumor because of intrinsic tumor heterogenity, clonal selection through metastatic process and following previous cytotoxic treatments.
- Trial name
- MetAction (NCT02142036)
- Testing
- EMA-approved ATI based targeted therapy
- Where
- 2 sites in Norway
- Volunteers
- 50 people
- Sponsor
- Oslo University Hospital
Non-Small Cell Lung Cancer (NSCLC)
Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1
Importance: EGFR tyrosine kinase inhibitors (EGFR-TKIs) and PD-1/PD-L1 immune checkpoint inhibitors are widely used in the treatment of non-small cell lung cancer (NSCLC).
- Trial name
- NCT07036016
- Testing
- EGFR-TKI, PD-1/PD-L1 inhibitor, EGFR-TKI combined with PD-1/PD-L1
- Volunteers
- 67,818 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Stomach Neoplasms
Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer
1. Metastatic gastric cancer patients who failed standard treatment will be enrolled in this study. 2. After consent form, patient-derived cancer cell will be collected and tested with 3 kinds of drugs (sunitinib, gefitinib…
- Trial name
- NCT03170180
- Testing
- Sunitinib, Gefitinib, Imatinib
- Where
- South Korea
- Volunteers
- 66 people
- Sponsor
- Samsung Medical Center
Lung Cancer
Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00062270
- Testing
- cisplatin, docetaxel, gefitinib
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
NSCLC
Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study
This study is being carried out to see if adding ZD1839 to other standard supportive care is more effective than standard supportive care alone for the treatment of patients with NSCLC whose disease has recurred after previous…
- Trial name
- NCT00242801
- Testing
- Gefitinib
- Where
- 211 sites in Argentina, Australia and 30 more
- Volunteers
- 1,692 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib
The objective of the Phase I step is to estimate the MTD at a dose level up to 50 mg/day (i.e., overseas recommended Phase II dose) in patients with advanced NSCLC and to determine the recommended dose for the Phase II step.
- Trial name
- NCT00711594
- Testing
- BIBW 2992 MA2 40mg/day, BIBW 2992 MA2 50mg/day, BIBW 2992 MA2 20mg/day
- Where
- 20 sites in Japan
- Volunteers
- 74 people
- Sponsor
- Boehringer Ingelheim
Salivary Gland Cancer
Iressa Study in Patients With Salivary Gland Cancer
The goal of this clinical research study is to learn if ZD1839 (Iressa®, gefitinib can help to shrink or slow the growth of advanced, recurrent, or metastatic salivary gland cancer. The safety of this drug will also be studied.
- Trial name
- NCT00509002
- Testing
- Gefitinib
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00103051
- Testing
- cisplatin, gefitinib, gemcitabine hydrochloride
- Where
- Netherlands
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Non Small Cell Lung Cancer (NSCLC)
Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer
Combining nimotuzumab to gefitinib may not only potentiate cellular cytotoxicity, but may also assist in overcoming inherent or acquired resistance to gefitinib alone.
- Trial name
- DATE (NCT01498562)
- Testing
- Gefitinib and Nimotuzumab, Gefitinib
- Where
- South Korea
- Volunteers
- 160 people
- Sponsor
- Yonsei University
Urothelial Carcinoma, Bladder Cancer
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
Background: Advanced urothelial cancer has no cure. But only a few chemotherapy drugs have been tested for it. The Co-eXpression ExtrapolatioN (COXEN) model predicts if cells respond to treatment.
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
- Trial name
- NCT02788201
- Testing
- 75 approved agents, COXEN
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Carcinoma
ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer
The primary objective of the trial is to determine the Maximum tolerated dose, if any, of the combination of daily ZD1839 250 mg with carboplatin AUC 2 and 60 Gray (Gy) irradiation and up to 45 mg/m2 paclitaxel.
- Trial name
- NCT00252798
- Testing
- Gefitinib, Carboplatin, Paclitaxel
- Where
- 2 sites in Australia
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01243398
- Testing
- quality-of-life assessment
- Where
- United Kingdom
- Volunteers
- 450 people
- Sponsor
- University of Oxford
Squamous Cell Carcinoma of Bronchus
Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy
Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC).
- Trial name
- SIIS (NCT01485809)
- Testing
- Gefitinib
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- Seoul Veterans Hospital
Non Small Cell Lung Cancer
Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim
Patients enrolled on this study will have been diagnosed with non-small cell lung cancer which cannot be removed by an operation.
- Trial name
- NCT00280787
- Testing
- Paclitaxel, Carboplatin, CPT-11
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Tumors
Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
This study will determine the safety profile and maximum tolerated dose (MTD) of orally administered gefitinib on a weekly and twice weekly schedule.
- Trial name
- AGUS (NCT00127829)
- Testing
- Gefitinib
- Where
- 2 sites in United States
- Volunteers
- 66 people
- Sponsor
- AstraZeneca
Breast Cancer
Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of gefitinib in treating patients who have metastatic breast…
- Trial name
- NCT00066339
- Testing
- gefitinib
- Where
- Belgium
- Volunteers
- 44 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Advanced Tumor
Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer
Phase I AZD2171 in combination with ZD1839 study recruiting patients with advanced cancer
- Trial name
- NCT00502060
- Testing
- AZD2171, ZD1839
- Where
- 3 sites in Netherlands
- Volunteers
- 65 people
- Sponsor
- AstraZeneca
The Primary Study Metric is Progression-free Survival (PFS)
A Retrospective Study of Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant Lung Cancer
Objective: To investigate the efficacy and safety of radiotherapy combined with EGFR-KI in the treatment of stage III EGFR mutant lung cancer.
- Trial name
- NCT05934461
- Volunteers
- 48 people
- Sponsor
- Laibin People's Hospital
NSCLC
Iressa v BSC (Best Supportive Care) in First Line NSCLC
The purpose of the study is to determine if the addition of Iressa to Best Supportive Care treatment will increase the progression free survival of chemo-naïve, poor performance status patients, with stage IIIB or IV NSCLC.
- Trial name
- INSTEP (NCT00259064)
- Testing
- Gefitinib
- Where
- 36 sites in Australia, Canada and 3 more
- Volunteers
- 216 people
- Sponsor
- AstraZeneca
Unspecified Adult Solid Tumor, Protocol Specific
Tetracycline in Preventing Skin Rash in Patients Who Are Receiving Drugs Such as Gefitinib and Cetuximab for Cancer
RATIONALE: Tetracycline may be effective in preventing skin rash that is caused by treatment with drugs such as gefitinib or cetuximab.
- Trial name
- NCT00091247
- Testing
- tetracycline hydrochloride
- Where
- 69 sites in United States
- Volunteers
- 130 people
- Sponsor
- Alliance for Clinical Trials in Oncology